Sean Fletcher

More insights from @MSKCancerCenter re: N+ #prostatecancer. Confirming PSMA PET ≠ PLND, PLND alone is not commonly curative, tx needs to be multimodal. #GU26 @SeanFletcherMD

Great night out with our all star fellows at #SUO2025 lo

Interested in learning about the oldest and largest urologic oncology fellowship in the world? Join us in our virtual open house wed Nov 12th at 7 pm EST Hear from faculty and current fellows!! mskcc.org/hcp-education-… Sign up: forms.gle/bE5nEzCuaczcVD…

Great opportunity to learn at #ECIW2025

New in @JAMAOnc: Our study of >11,000 PLCO participants shows that ~25% of elevated PSA values fall below threshold within a year, but persistent elevations rarely do (<10%), and should proceed directly to further eval. @SigridCarlsson @MariaPereMD @UrologyMSK @VickersBiostats

Check out our Clinical Consultation Guide on Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer, published in @EurUrolFocus @nirmishsingla @JCensits eu-focus.europeanurology.com/article/S2405-…

Family History of Prostate, Breast, Ovarian, and/or Pancreatic Cancer and Associations with Grade Reclassification in a Large Prostate Cancer Active Surveillance Cohort euoncology.europeanurology.com/article/S2588-… In a prospective cohort of 1,421 prostate cancer patients on active surveillance, family history of #ProstateCancer (FH-Pr) was associated with a higher risk of grade reclassification, including progression to Gleason grade ≥3, whereas family history of breast, ovarian, or pancreatic cancer (FH-BOPa) was not. Among 349 patients who underwent radical prostatectomy, no family history was linked to adverse pathological features. These findings suggest that patients with a FH of prostate cancer can remain on active surveillance but may benefit from closer monitoring. @ClaireDlc @SeanFletcherMD @KatarzynaMacura @LotanLab William B. Isaacs @brady_Urology Christian P. Pavlovich @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

Major congrats to @LoganGalanskyMD & huge win for @BostonChildrens !

Out in @BJUIjournal: Retro cohort study on detection of GG2+ PCa on systematic biopsy outside of MRI ROI (n=481 biopsies @brady_urology) - 6.4% with GG2+ outside of ROI - 1.5% with GG2+ contralateral to ROI - No association w baseline factors (e.g. PSA-D) bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Honor and a pleasure to end residency with the Peds team 🫡 @DrG_PedsUro @heathernoellemc @dr_chad11 @CharlotteWuMD @VictoriaMaxon @madip_pac

Feels a bit surreal to be done — so grateful to have trained @brady_urology with world class faculty, staff & co-residents!

Major congrats to @ztonysu & @theNCI !!

Great pic of our recent VP @SBoorjian and @brady_urology learners! Again thank u for a great visit. @urogabe @SeanFletcherMD @LoganGalanskyMD @VictoriaMaxon @MarkAlshakMD

Thanks to @samhaywoodmd for highlighting our work in “Three Papers that Influenced my Practice” during #SUO session #AUA2025 @y_bhanji @SUO_YUO @UroOnc

Come on over to booth #361 to learn about our residency program, try out our VR surgery simulator, and meet with our team! @brady_urology @SLICE_JHU @aghazimd #AUA2025

Last night's Brady dinner- an evening of good food and conversation with Dr. Allaf, Kate, and our wonderful residents and fellows!

Congrats and welcome!!

Proud to share our latest DISSRM publication, which explores the relationship between tumor size and growth rates in small renal masses among patients undergoing active surveillance bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Excited to share our team’s work @brady_urology describing the evolution of AS for PCa in the modern era! Is Confirmatory Biopsy Still Necessary for Active... : Journal of Urology journals.lww.com/auajuro/abstra…

👏🏾👏🏾👏🏾 5 star recruit, go Nora! @nmhaney